Clearbridge's device can detect CTCs without antibodies

06/5/2013 |

Clearbridge BioMedics has introduced the ClearCell FX technology, which can detect circulating tumor cells without the need for antibodies or other labeling techniques, this article says. The system, co-developed with Cambridge Consultants, incorporates a tiny device called the CTChip FR that employs fluid dynamics to isolate CTCs from other cells in blood for further analysis.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN